Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies

Status unconfirmed · Phase 1/Phase 2

Conditions studied: Mesothelioma, Glioblastoma, Renal Cell Carcinoma, Non Small Cell Lung Cancer, Melanoma, Pancreatic Ductal Adenocarcinoma, Gastric Cancer, Squamous Cell Carcinoma of Head and Neck, Cholangiocarcinoma, Breast Cancer, Ovarian Cancer, Cervical Cancer, Endocervical Cancer, Colorectal Cancer, Esophageal Cancer

In brief

Study of NGM707 as Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies

Key facts

Study ID

NCT04913337

Run by

NGM Biopharmaceuticals, Inc

People needed

179

Starts

2021-06-09

Expected to finish

2025-07-01

Last updated by the study team

2024-10-02

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Histologically or cytologically documented locally advanced or metastatic solid tumor malignancy.
• Progressed or was intolerant to all available therapies known to confer clinical benefit appropriate for their tumor type, and for which the patient was eligible and willing to receive, or refused SOC treatments that are perceived to have marginal clinical benefit.
• Adequate bone marrow, kidney and liver function.
• Performance status of 0 or 1.
• Resolved acute effects of any prior therapy to baseline severity or CTCAE Grade 1 except for AEs not constituting a safety risk by Investigator judgement.

You may not qualify if…

• Prior treatment targeting ILT2 and/or ILT4 or targeting HLA-G.

Where it is running

• NGM Clinical Study Site — Los Angeles, California, United States
• NGM Clinical Study Site — Newport Beach, California, United States
• NGM Clinical Study Site — Santa Monica, California, United States
• NGM Clinical Study Site — Santa Rosa, California, United States
• NGM Clinical Study Site — Lone Tree, Colorado, United States
• NGM Clinical Study Site — Washington D.C., District of Columbia, United States
• NGM Clinical Study Site — Sarasota, Florida, United States
• NGM Clinical Study Site — Baltimore, Maryland, United States
• NGM Clinical Study Site — Boston, Massachusetts, United States
• NGM Clinical Study Site — Grand Rapids, Michigan, United States
• NGM Clinical Study Site — Omaha, Nebraska, United States
• NGM Clinical Study Site — Albany, New York, United States
• NGM Clinical Study Site — Greenville, South Carolina, United States
• NGM Clinical Study Site — Dallas, Texas, United States
• NGM Clinical Study Site — Dallas, Texas, United States
• NGM Clinical Study Site — Houston, Texas, United States
• NGM Clinical Study Site — San Antonio, Texas, United States
• NGM Clinical Study Site — San Antonio, Texas, United States
• NGM Clinical Study Site — Blacksburg, Virginia, United States
• NGM Clinical Study Site — Vancouver, Washington, United States
• NGM Clinical Study Site — Seoul, South Korea
• NGM Clinical Study Site — Seoul, South Korea
• NGM Clinical Study Site — Seoul, South Korea
• NGM Clinical Study Site — New Taipei City, Taiwan
• NGM Clinical Study Site — Taichung, Taiwan

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.